Actively Recruiting
Thulium Laser and Growth Factors for Androgenetic Alopecia
Led by Universitätsklinikum Hamburg-Eppendorf · Updated on 2025-07-23
30
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Androgenetic alopecia (AGA) is a common cause of hair loss worldwide. It mainly affects the frontal and parietal regions of the scalp in up to 70 % of men and 40 % of women and has a significant negative psychological and emotional impact on those affected. Various therapies are currently approved for the treatment of AGA in men and women, including topical minoxidil, topical or systemic finasteride, platelet-rich plasma and hair transplantation. In addition to these pharmacological and surgical interventions, laser therapies including thulium laser with growth factors have gained popularity. Despite the clinical use of the thulium laser with growth factors in combination with LED phototherapy, there are only a few studies to date that have adequately investigated the objective and patient-side benefits of this therapy.
CONDITIONS
Official Title
Thulium Laser and Growth Factors for Androgenetic Alopecia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women aged 18 and over
- Good general health with no relevant previous illnesses
- Diagnosed with androgenetic alopecia (AGA)
- Able to understand and willing to provide informed consent
- Willing and able to attend follow-up visits
You will not qualify if you...
- Under 18 years of age
- Pregnant or breastfeeding women
- Scarring alopecia or alopecia caused by skin diseases or chemical/physical damage
- Significant scarring or open wounds in the treatment area
- Presence of metallic implants in the head region
- Mental illnesses such as psychoses or body perception disorders
- Use of isotretinoin, other retinoids, psychotropic drugs, coumarins, or heparins within the last 2 weeks
- Resurfacing treatments of the affected area within 2 months before or during the study
- Tendency to excessive scarring
- Lack of informed consent or data protection agreements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Medical Center Hamburg-Eppendorf
Hamburg, Free and Hanseatic City of Hamburg, Germany, 20246
Actively Recruiting
Research Team
L
Lynhda Nguyen, Dr. med.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here